Oak Hill Bio
PrivateLast Round
Series A
Jun 1, 2026
Total Funding Raised
$32.5M
Momentum Score
25 /100
Company Overview
Oak Hill Bio is a biotechnology company that acquires and develops deprioritized late-stage rare disease drugs.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Oak Hill Bio Comps
Public and private peers based on sector, stage, and business model.
Oak Hill Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Jun 1, 2026 | ||||
| Seed | Feb 1, 2022 |
Oak Hill Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series A |
| Balyasny Asset Management L.P. | Series A |
| venBio | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 1, 2026
$33M round led by Balyasny Asset Management, Janus Henderson, and venBio.
- Apr 15, 2026
Monthly visitors grew 161% MoM, reaching 2K.
Oak Hill Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Oak Hill Bio's valuation, stock price, and market status.
